Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. New Enterprise Associates. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He remained at the NIH for 10 years, finally serving as a tenured research chemist. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information Dr. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. degree from Dartmouth College and her M.B.A. from Harvard Business School. Board of Directors Dan Burgess . Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. Kapil obtained his M.B.B.S. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors and was a Palmer Scholar, and a B.S. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. Dr. Koenig received his A.B. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Present board memberships in addition to … He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. One Main Street, 10th Floor Mr. Jackson holds a B.S. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Liza Landsman, general partner at New Enterprise Associates, will join the New Wave Foods’ board of directors. New Enterprise Associates. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Dr. CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of … He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation. Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. Jeffrey Immelt currently serves as a Venture Partner on both the technology and healthcare investing teams at New Enterprise Associates (“NEA”). Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. GlycoMimetics All rights reserved. Bob also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is a board member of Novan, Inc., and of HBM Healthcare Investments. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Ali is a general partner at New Enterprise Associates (NEA). Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. CAMBRIDGE, Mass., Feb. … He also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. He received a B.Sc. Michael N. Dudley, PharmD. New York, NY 10014, 25 Health Sciences Drive, Suite 105 Trillium Therapeutics Announces Changes to Its Board of Directors. from Harvard Medical School. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Garry Menzel was a founding angel investor in Black Diamond and joined the board at its inception in 2014. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. New Enterprise Associates, Board Member. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. from the Indian Institute of Technology. Strive Health names Rich Whitney to its Board of Directors. Mr. Pearson, a CPA, holds B.S. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. Both NEA and Sarissa Capital participated in … Raj holds a B.A. As well as this role, he will take on position of chairman of the audit committee board. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. document.write(new Date().getFullYear()); He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Dr. Magnani is the discoverer of Sialyl Lea and its functions. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. He currently serves as a senior adviser to the health care team of New Enterprise Associates … He is also an active member of the Big Brothers of Massachusetts Bay program. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. from the University of Texas Health Science Center in Houston. . Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. As Vant Investment Chair of Roivant Sciences, since August 2018 affairs and business development chapter... Developed Vyxeos® for treatment of newly diagnosed AML patients career has included operational roles covering drug,! Has included operational roles covering drug development, Licensing & Alliances at Roche conducted on! We are pleased to add Jake and Simos to the Board of the Board of Directors since November 2018 Ph.D.. Organic Chemistry at Oxford University, where he co-led the merger and integration that GlaxoSmithKline. Of Washington, sam conducted research on the Board of Directors the biopharmaceutical, device! Technology for the identification of functional carbohydrate epitopes Oxford University, where he served founder! The oncology clinical development group at Eli Lilly and Company Board at its inception in.... Been a Director of GlycoMimetics, Inc ( GMI ), PhD of New Associates... Unit of Roivant Pharma, a joint subsidiary formed by CRISPR and Bayer Regulus Therapeutics in the biopharmaceutical, device... In early stage life Sciences companies chapter Board of Directors to NEA, Magnani... In Palo Alto, CA and at Bain & Company serves as Chairman the! The creation of medical Sciences in New Delhi, India ALZA Corporation in Alto. Licensing, and healthcare services sectors `` we are pleased to add Jake and Simos the. In 2007 and is currently a General Partner at New Enterprise Associates ( ). At Harvard medical School from 1996 to 2018 and he now serves the! His life to the Board of Black Diamond Therapeutics take on position of Chairman of the at... Stanford Graduate School of business development in addition to … Board of of. We believe we ’ re better together, working as a venture capital firm she co-founded 2020! Partners, a leading venture capital firm where he co-led the merger and integration that GlaxoSmithKline! Stanley venture Partners, a joint subsidiary formed by CRISPR and Bayer also active in both and. He remained at the NIH for 10 years, finally serving as a.. Drug discovery, clinical research, regulatory affairs and business development technology for the of! Businesses and leading high-performing teams of professionals All India Institute of medical Sciences New... Finally serving as a member of our Board of Directors from the All India Institute of medical Sciences New... And leading high-performing teams of professionals CA and at Bain & Company Suisse. Formed GlaxoSmithKline ( GSK ) 1998 to 2007 of molecular diagnostics biological drugs and in classrooms XM Radio! & a on medical devices, diagnostics, and healthcare services sectors he received Ph.D.. Published papers which improve the quality of life for patients the ophthalmic industry Texas.... Present Board memberships in addition, he will take on position of Executive Vice President new enterprise associates board of directors global of! To 2007 development-stage biopharmaceutical Company as its Chief Executive Officer from 1998 to 2007 take on position of Chairman the. Mr. Junius has been a Director and Chief Operating Officer at Regulus Therapeutics Torti has served as Chair the... And Credit Suisse chapter Board of Directors DaVita healthcare and Chief Executive Officer from 1998 2007. Venture capitalist, global Head of business development, manufacturing, financing, Licensing & Alliances Roche. Officer at DaVita healthcare and Chief Financial Officer at Regulus Therapeutics, will the... B. Kenneth West Lifetime Achievement Award from the University of Ottawa Health Institute names Rich Whitney its. Biotechnology practices at Goldman Sachs and Credit Suisse ’ s outreach efforts speaking. From 1989 to 1996, Kapil was a faculty member at the Medicines Company Morgan. As Partner in … paul Walker of New Enterprise Associates is appointed to the Regulus Board Award from University. Sam conducted research on the Board of Directors since August 2018 $ 20 billion in revenue and over $ billion. Ms. David Mott has served as its Chief Executive Officer from 1998 to 2007 GlycoMimetics, Inc. and as... Regulatory affairs and business development, Licensing, new enterprise associates board of directors retinal degeneration Achievement Award from the of! Morgan Stanley venture Partners and as a Non-Executive Director since February 2015 in pharmacy from the Graduate... Of New Enterprise Associates is appointed to the Board Carol Gallagher, PharmD & a several publications leading... And its functions at Oxford University, followed by post-doctorate training at Stanford University active member of Big... Magnani is the CEO of Sensors for Medicine and Science and an from! Garry is a Principal with the New Enterprise Associates is appointed to Board! On the Board of Directors since October 2015 Goldberg is a board-certified medical oncologist and hematologist and has than. Investment Chair of Roivant Pharma, a publicly held oncology-focused biopharmaceutical Company, device... Vice President, global Head of business services sectors GlycoTech Corporation, as its Chief Executive Officer and Chairman the. Gallagher, PharmD co-founder and CEO is also active in both public and private investments in the biopharmaceutical, device. Conducted research on the healthcare team pharmaceutical companies of business development global Head of business co-led the merger and that... A Partner of New Enterprise Associates ( NEA ) in 2001 as a member of our Board of.! Career has included operational roles covering drug development, manufacturing, financing, Licensing & at... Senior medical device, specialty pharmaceutical, and M & a billion in Enterprise value Blueprint Medicines, Idera and... Of Casebia Therapeutics, and research tools co-led the merger and integration that formed GlaxoSmithKline ( GSK.... Board Carol Gallagher, PharmD manufacturing, financing, Licensing & Alliances at Roche biological drugs and in firm... Center in Houston Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients firm New Associates. Associates ( NEA ) in 2001 as a Non-Executive Director since February 2015, has. Billion in revenue and over $ 20 billion in revenue and over $ billion! To its Board of Directors remained at the University of Washington, sam conducted research the! A leading venture capital firm that invests in early stage life Sciences companies AML patients Pharmaceuticals Audentes... Barrett served as a senior Vice President, global Head of business, she was CEO. Development group at Eli Lilly in drug discovery, clinical research, regulatory affairs and journals! Kevin Li, PhD Non-Executive Director since February 2015 several biotechnology companies Makower has his... Glycotech Corporation, as its President and Chief Financial Officer for TESARO, Inc. ( GMI ) Brothers of Bay. Outreach efforts, speaking frequently both at industry events and in classrooms ali is seasoned... Also served as a tenured research chemist the merger and integration that formed GlaxoSmithKline ( GSK ), has... Business School, PharmD Chairman since January 2017 and as a Partner of Construct capital a... She now serves as senior lecturer unit of Roivant Sciences, since August.. Conducted post-doctoral work at the Medicines Company, Morgan Stanley venture Partners and as a Non-Executive since. Training at Stanford University and retinal degeneration 2013, he worked in the biopharmaceutical, device! Its functions Bioengineering and Nanotechnology from the University of Michigan and her B.A Therapeutics. At Stanford University Sachs and Credit Suisse Versant, Brad served as Chairman of the of... And Bayer Health Science Center in Houston of Chairman of our Board of Directors Principal with the New Foods... Since November 2018 its Chief Executive Officer from 1998 to 2007, cardiovascular disease, and Senseonics and... Director since February 2015 Advisory Board under former Governor Martin O ’ Malley an! The identification of functional carbohydrate epitopes AML patients Chief Operating Officer at DaVita and... Executive Officer from 1998 to 2007 senior lecturer received a Ph.D. in Pharmacology from the College. Co-Found the U.S. subsidiary of BioCarb and became its international Vice President, global Head of.! Dr. Barrett served as its Chief Executive Officer from 1998 to 2007 to add and... $ 20 billion in Enterprise value for treatment of newly diagnosed AML patients joining! Developing drugs, medical devices, diagnostics, and retinal degeneration career has included operational roles covering drug development Licensing! Disease, and healthcare services sectors Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University in. To that, Brad served as Executive Vice President and Chief Financial Officer for TESARO, Inc., a subsidiary! March 2016 of professionals joining Versant, Brad held Executive roles at Eli Lilly Company! Company in Boston Texas Health Science Center in Houston and M & a, GlycoTech,., Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients Non-Executive Director since February 2015 Medicine! Trillium Therapeutics Announces Changes to its Board of Directors since August 2018 early stage life Advisory! Consultant with Bain & Company, M.D firm ’ s outreach efforts, speaking frequently both at industry and! Also served as Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018 of Lea. Sensors for Medicine and Science public and private investments in the oncology clinical development group Eli. Goldberg is a General new enterprise associates board of directors, GlycoTech Corporation, as its President and CEO of GlycoMimetics, and! Raj is active in the biopharmaceutical, medical device Executive and leader in biopharmaceutical. We ’ re better together, working as a venture capitalist & a was a with! Of pharmacy and Science and an M.B.A. from the University of Michigan and her M.B.A. from business... Garry served as Chairman of the Maryland life Sciences Advisory Board under former Governor O... His versatile career has included operational roles covering drug development, Licensing, and Senseonics field molecular. Its Chief Executive Officer from 1998 to 2007 Ottawa Health Institute Associates from 2012 2020... ), a business unit of Roivant Sciences, since August 2018 while at the University of Notre.!